Oncolytics Biotech (TSE:ONC) Insider Allison Hagerman Purchases 10,000 Shares

Oncolytics Biotech Inc. (TSE:ONC) insider Allison Hagerman acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average price of C$1.14 per share, for a total transaction of C$11,400.00. Following the completion of the acquisition, the insider directly owned 79,842 shares of the company’s stock, valued at C$91,019.88. The trade was a 14.32% increase in their position.

Oncolytics Biotech Price Performance

ONC stock opened at C$14.90 on Friday. Oncolytics Biotech Inc. has a 52-week low of C$0.44 and a 52-week high of C$2.08. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The stock has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The business has a fifty day moving average of C$14.90 and a two-hundred day moving average of C$13.03.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) EPS for the quarter. As a group, research analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.